Brokers Offer Predictions for Elevance Health Q1 Earnings

Elevance Health, Inc. (NYSE:ELV) – Analysts at Zacks Research reduced their Q1 2025 EPS estimates for Elevance Health in a research note issued to investors on Wednesday, December 18th. Zacks Research analyst K. Dey now anticipates that the company will post earnings per share of $10.76 for the quarter, down from their previous forecast of $10.87. The consensus estimate for Elevance Health’s current full-year earnings is $32.96 per share.

Elevance Health (NYSE:ELV) last issued its earnings results on Thursday, October 17th. The company reported $8.37 EPS for the quarter, missing the consensus estimate of $9.66 by ($1.29). Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. The business had revenue of $44.72 billion for the quarter, compared to analysts’ expectations of $43.47 billion. During the same quarter in the prior year, the business posted $8.99 earnings per share. The business’s revenue for the quarter was up 5.3% on a year-over-year basis.

A number of other analysts also recently issued reports on the stock. Royal Bank of Canada dropped their price target on shares of Elevance Health from $585.00 to $478.00 and set an “outperform” rating on the stock in a report on Friday, October 18th. Truist Financial restated a “buy” rating and issued a $520.00 target price (down previously from $620.00) on shares of Elevance Health in a report on Friday, October 18th. Argus lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a research note on Friday, October 18th. TD Cowen dropped their price target on Elevance Health from $589.00 to $484.00 and set a “buy” rating on the stock in a research note on Monday, October 21st. Finally, Wells Fargo & Company cut their price objective on Elevance Health from $593.00 to $495.00 and set an “overweight” rating for the company in a report on Monday, November 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $539.20.

Elevance Health Price Performance

NYSE ELV opened at $365.96 on Friday. Elevance Health has a one year low of $362.21 and a one year high of $567.26. The stock has a 50-day moving average of $409.70 and a 200 day moving average of $489.05. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.50 and a current ratio of 1.50. The company has a market capitalization of $84.87 billion, a price-to-earnings ratio of 13.34, a PEG ratio of 1.15 and a beta of 0.83.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, December 20th. Investors of record on Thursday, December 5th were paid a dividend of $1.63 per share. This represents a $6.52 dividend on an annualized basis and a dividend yield of 1.78%. The ex-dividend date was Thursday, December 5th. Elevance Health’s dividend payout ratio (DPR) is 23.77%.

Insider Buying and Selling

In related news, EVP Charles Morgan Kendrick, Jr. sold 7,417 shares of Elevance Health stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $432.14, for a total transaction of $3,205,182.38. Following the sale, the executive vice president now owns 8,423 shares of the company’s stock, valued at approximately $3,639,915.22. This trade represents a 46.82 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.35% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Elevance Health

Institutional investors have recently added to or reduced their stakes in the stock. Raelipskie Partnership purchased a new position in Elevance Health during the third quarter valued at $26,000. PSI Advisors LLC bought a new position in shares of Elevance Health during the 3rd quarter valued at about $27,000. Strategic Financial Concepts LLC purchased a new position in shares of Elevance Health during the second quarter valued at about $30,000. Eastern Bank bought a new stake in shares of Elevance Health in the third quarter worth about $31,000. Finally, Dunhill Financial LLC lifted its position in shares of Elevance Health by 57.8% in the third quarter. Dunhill Financial LLC now owns 71 shares of the company’s stock worth $37,000 after buying an additional 26 shares in the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.